The findings of current study convincingly suggested that selected 1,3,4 oxadiazole derivatives are potent inhibitors of VEGFR 2 compared to EGFR and can be used in the treatment of cancers where selective VEGFR2 inhibitors are required i.e., renal cancer and to mitigate angiogenesis in other cancers. Here, EGFR is linked to cancer.